Clinical Trials Logo

Molluscum Contagiosum clinical trials

View clinical trials related to Molluscum Contagiosum.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05937672 Recruiting - Clinical trials for Molluscum Contagiosum

Cold Atmospheric Plasma Device Extension Study

Start date: September 18, 2023
Phase: Phase 3
Study type: Interventional

Patients between 4-21 years of age with at least one wart or molluscum lesion are eligible to participate in this study. The duration of the study is a minimum of 4 weeks with the maximum duration of monthly treatments for one year, depending on lesion clearance. The number of lesions will be chosen by the dermatologist. Patients who opt to participate will receive non-thermal, or cold, atmospheric plasma to treat all lesions selected. Safety profile as well as changes in size, pain and appearance will be measured. Photographs and dermatologist impressions will be used to measure treatment response.

NCT ID: NCT05680181 Recruiting - Clinical trials for Molluscum Contagiosum

Study of a Cohort of Children With Molluscum Contagiosum (MC) Treated With a 5% Solution of Potassium Hydroxide (Molutrex®) Applied Locally to the Skin

SERENITE
Start date: January 20, 2023
Phase:
Study type: Observational

Molutrex® a 5% potassium hydroxide solution for topical application to the skin. Molutrex® is intended for the superficial treatment of certain types of warts, molluscum contagiosum and is composed of potassium hydroxide (5%) purified water. With regard to the 2017/745 RDM, he is a class IIa medical device. In accordance with Regulation (EU) 2017/745 of the European Parliament and of the Council of April 5, 2017 relating to medical devices, as part of the Molutrex® Post-Marketing Monitoring Plan, the objective of this study is to have data on the performance , safety and suitability for real-life use of Molutrex® in a prospective cohort of patients with molluscum contagiosum. Since molluscum contagiosum is most prevalent in children, and potassium hydroxide is used very little in adults (because most often they are immunocompromised patients requiring other antiviral treatments), the study will be conducted in children aged 2 to 10 years. This population represents the majority of patients treated with Molutrex®, although the product can be used in adults. The study includes 2 visits, the objective of the study being to evaluate the percentage of children healed at 45 days, healing defined by a reduction of more than 90% in the number of lesions present at inclusion in the study.

NCT ID: NCT04476186 Recruiting - Clinical trials for Molluscum Contagiosum

The Effectiveness of Oral Acyclovir in the Treatment of Molluscum Contagiosum in Children

Start date: June 15, 2020
Phase: N/A
Study type: Interventional

The investigators will study the effectiveness of acyclovir in the treatment of molluscum contagiosum in assiut university hospital - dermatological out patient clinic the treatment group will receive acyclovir 200 mg 5 times per day the controlled group will receive local KOH solution

NCT ID: NCT02759900 Recruiting - Actinic Keratosis Clinical Trials

Using a Cold Atmospheric Plasma Device to Treat Skin Disorders

Start date: January 2016
Phase: N/A
Study type: Interventional

This study examines the efficacy of a non-thermal, atmospheric plasma device in the treatment of skin disorders